HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human

Immobilized HLA-A*11:01&B2M&KRAS G12D TCR at 5 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human, His Tag with the EC50 of 0.39 μg/ml determined by ELISA.

The purity of HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human, His Tag captured on CM5 Chip via Anti-His Antibody can bind HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR with an affinity constant of 14.91 nM as determined in SPR assay (Biacore T200).

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Cat. No.	Z06617
Size	100 μg : Quote 500 μg : Quote Buy in bulk
Quantity
TAT
Price	¥63,425.00


Ask us a question

Product Introduction

Species

Human

Protein Construction

HLA-A11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer[ Gly25-Thr305(HLA-A11:01),Ile21-Met119(B2M) and VVVGADGVGK peptide] Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK	His	Avi
N-term		C-term

Purity

> 95% as determined by BisTris PAGE

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.

Expression System

HEK293

Theoretical Molecular Weight

50.3 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples

The purity of HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Background

Target Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Synonyms	MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His & Avi, Human

サポート

会社情報

サポート

会社情報